Last reviewed · How we verify
SPIKEVAX Bivalent
At a glance
| Generic name | SPIKEVAX Bivalent |
|---|---|
| Also known as | SPIKEVAX Bivalent BA.1, SPIKEVAX BIVALENT BA.4/5, SARS-CoV-2-mRNA vaccine |
| Sponsor | ModernaTX, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial (PHASE3)
- A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine
- Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.
- Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
- COVID-19 Fourth Dose Study in Australia (PHASE3)
- Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults (PHASE2)
- COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 (PHASE4)
- COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPIKEVAX Bivalent CI brief — competitive landscape report
- SPIKEVAX Bivalent updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI